Loading clinical trials...

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD) | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Study of the Combination of Anecortave Acetate and Triamcinolone Acetonide for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

Pilot Study of the Combination of Anecortave Acetate 15mg Delivered by Posterior Juxtascleral Injection and Triamcinolone Acetonide 4mg Delivered by Intravitreal Injection for the Treatment of Exudative Age-Related Macular Degeneration (AMD)

NCT00211419•Manhattan Eye, Ear & Throat Hospital

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety of combining juxtasclerally administered anecortave acetate 15 mg with triamcinolone acetate 4 mg administered intravitreally following photodynamic therapy with verteporfin for the treatment of exudative age-related macular degeneration (AMD).

Eligibility

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. A male or female with evidence of exudative age-related macular degeneration with clinical/angiographic/optical coherence tomography (OCT) findings of subfoveal choroidal neovascularization (CNV) which has not responded to current therapy
•2. Baseline best-corrected visual acuity (BCVA) 20/40 to 20/640
•3. Patient must be willing and able to comply with the protocol and provide informed consent.

Exclusion Criteria

•1. Patients on intravenous, subcutaneous, or anticoagulant therapy (with the exception of aspirin and antiplatelet therapy) and cannot take a 5 day holiday from therapy prior to the injection procedure. Note: Patients on oral anticoagulant therapy may be considered to participate if the physician responsible for monitoring the anticoagulant therapy agrees that the patient may take a 5 day holiday from therapy prior to each anecortave injection. The attending doctor must notify the principal investigator and this notification will be made part of the source documentation. Anticoagulant therapy may resume either the evening of or the morning after the injection procedure.
•2. Patient with known glaucoma or steroid induced ocular hypertension
•3. Intraocular pressures of 21 mmHg or greater at time of entry into the study
•4. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions
•5. Patients who have undergone intraocular surgery within last 2 months or capsulotomy within last month in study eye
•6. Patient participating in any other investigational drug study
•7. Inability to obtain photographs to document CNV (including difficulty with venous access)
•8. Concomitant oral steroids or topical ophthalmic steroid use
•9. Sub-Tenon's injection of steroids within the past 6 months
•10. Patient with significant liver disease or uremia
+3 more criteria

Locations (1)

Manhattan Eye, Ear & Throat Hospital

New York, New York, United States

Key Dates

Last Updated

October 24, 2012

Conditions

Maculopathy, Age-Related

Interventions

Anecortave Acetate 15 mg

DRUG

Triamcinolone Acetate 4 mg

DRUG

Photodynamic Therapy with Verteporfin

PROCEDURE

Thermal Laser

PROCEDURE

Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)

NCT00051129

Macular DegenerationMaculopathy, Age-Related+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 24, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions